Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for NDA 022173

Expand all

ZYPREXA RELPREVV (OLANZAPINE PAMOATE)
EQ 210MG BASE/VIAL Marketing Status: Prescription

Active Ingredient: OLANZAPINE PAMOATE
Proprietary Name: ZYPREXA RELPREVV
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: EQ 210MG BASE/VIAL
Reference Listed Drug: Yes
Reference Standard: No
TE Code: 
Application Number: N022173
Product Number: 001
Approval Date: Dec 11, 2009
Applicant Holder Full Name: ELI LILLY CO
Marketing Status:  Prescription
Patent and Exclusivity Information

ZYPREXA RELPREVV (OLANZAPINE PAMOATE)
EQ 300MG BASE/VIAL Marketing Status: Prescription

Active Ingredient: OLANZAPINE PAMOATE
Proprietary Name: ZYPREXA RELPREVV
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: EQ 300MG BASE/VIAL
Reference Listed Drug: Yes
Reference Standard: No
TE Code: 
Application Number: N022173
Product Number: 002
Approval Date: Dec 11, 2009
Applicant Holder Full Name: ELI LILLY CO
Marketing Status:  Prescription
Patent and Exclusivity Information

ZYPREXA RELPREVV (OLANZAPINE PAMOATE)
EQ 405MG BASE/VIAL Marketing Status: Prescription

Active Ingredient: OLANZAPINE PAMOATE
Proprietary Name: ZYPREXA RELPREVV
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: EQ 405MG BASE/VIAL
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: 
Application Number: N022173
Product Number: 003
Approval Date: Dec 11, 2009
Applicant Holder Full Name: ELI LILLY CO
Marketing Status:  Prescription
Patent and Exclusivity Information

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English